Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vico Therapeutics
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy